Sign up USA
Proactive Investors - Run By Investors For Investors
Why invest in TRX?
Tissue Regenix Group PLC: THE INVESTMENT CASE

Tissue Regenix confirms US$30mln acquisition of bone graft specialist Cellright

Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln
picture of human skeleton
INVESTMENT OVERVIEW: TRX The Big Picture
Any shape you want with Cellright's matrix

Tissue Regenix PLC (LON:TRX) has splashed out US$30mln on a Texas-based rival, Cellright Technologies, to catapult it to the front of the growing US market for regenerative medicine and bone grafts.

Antony Odell, Tissue’s chief executive, said CellRight has a synergistic regenerative technology focused on bone that will complement its own dCELL soft tissue platform.

“Furthermore, a broad development pipeline of innovative products, multiple established distribution channels and a state of the art US-based manufacturing facility will enable us to increase our growth and market penetration, cementing our presence in the key US market, as well as providing an opportunity to enter new geographies.”

WATCH:Tissue Regenix chief Antony Odell on their 'transformational' Cellright acquisition

Tissue Regenix is funding the acquisition with a placing at 10p to raise £40mln. Woodford Asset Management took up almost 35% of the new shares issued, Invesco 31% and Perpetual 12.5% alongside a number of Tissue’s directors.

Tissue is developing skin graft, cartilage, ligament and valve replacement products based around its cell washing technology, which effectively eliminates the possibility of rejection by the body.

Cellright, meanwhile, has developed a technology that transforms human bone into a mouldable matrix that can be made into different shapes of malleable bone collagen scaffolds for a variety of graft purposes.

13 products to add to the portfolio

In particular, Cellright’s products are guaranteed to be osteo-inductive, or form new bone, and retain regenerative properties post-implantation.

CellRight has launched 13 products since 2012 and will increase Tissue’s US sales by 2.5 times.

The San Antonio-based company posted revenues US$5.42mln in 2016 and underlying profits that year were US$1.58mln.

Access to US$1.7bn market

The research House Hardman said the acquisition of CellRight gives Tissue Regenix immediate access to the US$1.7bn North American bone graft and substitutes market.

“Although the market is dominated by the large players – Medtronic, De Puy Synthes, Stryker – there is opportunity for new entrants with differentiated offerings,” said analyst Martin Hall.

“In addition, the existing products and commercial relationships of CellRight will pave the way for Tissue’s entrance to the US orthopaedic soft tissue market, valued at US$2bn, with OrthoPure in 2018.”

 

View full TRX profile View Profile

Tissue Regenix Group PLC Timeline

Related Articles

Woman stroking face
October 03 2017
Its SkinBiotix cream was assessed for cellular toxicity
Clinical Trial
August 04 2017
The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Cellmid's Maria Halasz with investors at Proactive's CEO Sessions
October 05 2017
Maria Halasz discussed rapidly growing hair care sales at Proactive's CEO Sessions.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use